Unknown

Dataset Information

0

A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.


ABSTRACT: INTRODUCTION:Patients presenting with advanced, recurrent, or metastatic endometrial cancer have limited treatment options. On behalf of the Gynecologic Oncology Group, we conducted this phase II trial of nintedanib (BIBF 1120), a potent small molecule triple receptor tyrosine kinase inhibitor of PDGFR ? and ?, FGFR 1/3, and VEGFR 1-3, in this population. OBJECTIVES:The primary objectives were to estimate event-free survival (EFS) at 6 months and the proportion of patients who have an objective tumor response. In addition, we sought to determine the nature and degree of toxicity. Secondary objectives were to estimate progression-free and overall survival. METHODS:This was a two-stage, single-arm phase II study. Eligible patients were treated with single-agent nintedanib at a dose of 200mg twice daily. RESULTS:Of 37 patients enrolled, 32 were eligible. There were zero complete and three partial responses for an overall response rate of 9.4% (90% 2-sided CI=2.6-22.5%). Seven patients (21.9%; 90% 2-sided CI=10.7-37.2%) were EFS at 6 months, with one patient continuing on study at the time of this writing. Serious toxicity included the following grade 3 events: gastrointestinal toxicity (5), neutropenia (1), edema (1), hypertension (1), and liver function abnormalities (5). CONCLUSIONS:Nintedanib lacked sufficient activity as a single agent to warrant enrollment to second stage. However, preclinical data indicate it may be synergistic with paclitaxel in a population of patients enriched for specific p53 mutations that result in loss of function. Subsequent studies may evaluate this agent in combination with paclitaxel.

SUBMITTER: Dizon DS 

PROVIDER: S-EPMC4373614 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

Dizon Don S DS   Sill Michael W MW   Schilder Jeanne M JM   McGonigle Kathryn F KF   Rahman Zia Z   Miller David S DS   Mutch David G DG   Leslie Kimberly K KK  

Gynecologic oncology 20141013 3


<h4>Introduction</h4>Patients presenting with advanced, recurrent, or metastatic endometrial cancer have limited treatment options. On behalf of the Gynecologic Oncology Group, we conducted this phase II trial of nintedanib (BIBF 1120), a potent small molecule triple receptor tyrosine kinase inhibitor of PDGFR α and β, FGFR 1/3, and VEGFR 1-3, in this population.<h4>Objectives</h4>The primary objectives were to estimate event-free survival (EFS) at 6 months and the proportion of patients who hav  ...[more]

Similar Datasets

| S-EPMC4278402 | biostudies-literature
| S-EPMC4642817 | biostudies-literature
| S-EPMC3107744 | biostudies-literature
| S-EPMC6546175 | biostudies-literature
| S-EPMC5728988 | biostudies-literature
| S-EPMC4469526 | biostudies-literature
| S-EPMC3700732 | biostudies-literature
| S-EPMC3568489 | biostudies-literature
| S-EPMC6235144 | biostudies-literature
| S-EPMC4615687 | biostudies-literature